Suppliers / Yangzhou Liberty Pharmaceutical

Yangzhou Liberty Pharmaceutical

China Updated 9 July 2026

Yangzhou Liberty Pharmaceutical is an API manufacturer based in China. It holds 3 active US drug master files. Its GMP standing is certified by US FDA and EMA. Its most recent recorded inspection, by US FDA, closed on 15 September 2023 as VAI.

3
active US DMFs
0
valid CEPs
2
registered plants 1 with an FDA FEI number
0
filings across 0 regulators
These figures were checked against the regulators' own files on 25 July 2026
Plants
1 of 1 confirmed
Inspections
1 of 1 confirmed
EU GMP
1 of 1 confirmed
Sources: FDA Establishment Registration, read 4 May 2026. FDA drug inspection classifications, read 4 May 2026. EudraGMDP (MIA + third-country GMP certs), read 4 May 2026.

Inspection history

  • 15 September 2023 VAI US FDA

NAI means no action indicated, VAI means voluntary action indicated, and OAI means official action indicated.

Registered plants

Site FDA FEI
Yangzhou, China Not on file
China, China 3009261735

What they file, and where

Molecule Regulators Docs
Doxycycline US FDA 3

Also appears on these molecule pages

Doxycycline API

Filings and GMP by regulator

Regulator Filings GMP certificates
US FDA None 1
EMA None 1

Questions about Yangzhou Liberty Pharmaceutical

Does Yangzhou Liberty Pharmaceutical hold a US DMF or a CEP?
Yangzhou Liberty Pharmaceutical holds 3 active US drug master files. A drug master file is a submission to the FDA describing how an ingredient is made; a CEP is the EDQM's certificate that the substance meets its European Pharmacopoeia monograph. Both are filings rather than approvals.
Is Yangzhou Liberty Pharmaceutical FDA-registered?
One site operated by Yangzhou Liberty Pharmaceutical carries an FDA establishment identifier (FEI), which means it is registered with the FDA as a drug establishment. Registration is not the same as approval or inspection clearance.
How did Yangzhou Liberty Pharmaceutical's last inspection go?
The most recent inspection on record closed on 15 September 2023 as VAI (Voluntary Action Indicated: issues were found but did not warrant regulatory action). 1 inspection is on file.
Where does Yangzhou Liberty Pharmaceutical manufacture?
2 registered sites are on record, in China (Yangzhou and China). Every site is listed on this page with the register it came from.
What does Yangzhou Liberty Pharmaceutical make?
1 molecule is on record against Yangzhou Liberty Pharmaceutical, including Doxycycline. Each links through to that molecule's full manufacturer list.
Which regulators recognise Yangzhou Liberty Pharmaceutical's GMP?
Current GMP certificates are on record from US FDA and EMA. GMP recognition covers the manufacturing site, separately from any filing on the substance itself.

Answered from this company's own record. Where a register holds nothing, the question is not asked rather than answered with a zero. How we count our figures.

Checking Yangzhou Liberty Pharmaceutical?

Ask Fred what the record holds on Yangzhou Liberty Pharmaceutical, including filings and inspection history.

Chat with Fred, your AI analyst
Opens WhatsApp. Free to start.

Open risk flags

  • The most recent inspection outcome was VAI, on 15 September 2023.

Comparable suppliers

Changzhou Pharmaceutical Factory shares 1 molecule Maithri Drugs shares 1 molecule Gland Pharma shares 1 molecule Raks Pharma shares 1 molecule Hovione Farmaciência shares 1 molecule

Ranked by shared active ingredients where we have them, otherwise by country and comparable credentials.

Sources on this page

FDA
Drug master files, establishment registration, inspection classifications
EDQM
Certificates of suitability
EudraGMDP and national regulators
GMP certificates